U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C2H8O7P2
Molecular Weight 206.0284
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ETIDRONIC ACID

SMILES

CC(O)(P(=O)(O)O)P(=O)(O)O

InChI

InChIKey=DBVJJBKOTRCVKF-UHFFFAOYSA-N
InChI=1S/C2H8O7P2/c1-2(3,10(4,5)6)11(7,8)9/h3H,1H3,(H2,4,5,6)(H2,7,8,9)

HIDE SMILES / InChI
Etidronate is a salt of etidronic acid (brand name Didronel, also known as EHDP) a diphosphonate, which is indicated for the treatment of symptomatic Paget’s disease of bone and in the prevention and treatment of heterotopic ossification following total hip replacement or due to spinal cord injury. Didronel is not approved for the treatment of osteoporosis. This drugs acts primarily on bone. It can inhibit the formation, growth, and dissolution of hydroxyapatite crystals and their amorphous precursors by chemisorption to calcium phosphate surfaces. Inhibition of crystal resorption occurs at lower doses than are required to inhibit crystal growth. Both effects increase as the dose increases. Preclinical studies indicate etidronate disodium does not cross the blood-brain barrier. Didronel is not metabolized. The amount of drug absorbed after an oral dose is approximately 3 percent. Bisphosphonates, when attached to bone tissue, are absorbed by osteoclasts, the bone cells that breaks down bone tissue. Although the mechanism of action of non-nitrogenous bisphosphonates has not been fully elucidated, available data suggest that they bind strongly to hydroxyapatite crystals in the bone matrix, preferentially at the sites of increased bone turnover and inhibit the formation and dissolution of the crystals. Other actions may include direct inhibition of mature osteoclast function, promotion of osteoclast apoptosis, and interference with osteoblast-mediated osteoclast activation. Etidronic acid may promote osteoclast apoptosis by competing with adenosine triphosphate (ATP) in the cellular energy metabolism. The osteoclast initiates apoptosis and dies, leading to an overall decrease in the breakdown of bone.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: CHEMBL2366048
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
DIDRONEL

Approved Use

Didronel is indicated for the treatment of symptomatic Paget’s disease of bone and in the prevention and treatment of heterotopic ossification following total hip replacement or due to spinal cord injury. Didronel is not approved for the treatment of osteoporosis. Paget’s Disease: Didronel is indicated for the treatment of symptomatic Paget's disease of bone. Didronel therapy usually arrests or significantly impedes the disease process as evidenced by: --Symptomatic relief, including decreased pain and/or increased mobility (experienced by 3 out of 5 patients). --Reductions in serum alkaline phosphatase and urinary hydroxyproline levels (30 percent or more in 4 out of 5 patients). --Histomorphometry showing reduced numbers of osteoclasts and osteoblasts, and more lamellar bone formation. Bone scans showing reduced radionuclide uptake at pagetic lesions. In addition, reductions in pagetically elevated cardiac output and skin temperature have been observed in some patients. In many patients, the disease process will be suppressed for a period of at least 1 year following cessation of therapy. The upper limit of this period has not been determined. The effects of the Didronel treatment in patients with asymptomatic Paget's disease have not been studied. However, Didronel treatment of such patients may be warranted if extensive involvement threatens irreversible neurologic damage, major joints, or major weight-bearing bones. Heterotopic Ossification: Didronel is indicated in the prevention and treatment of heterotopic ossification following total hip replacement or due to spinal cord injury. Didronel reduces the incidence of clinically important heterotopic bone by about two-thirds. Among those patients who form heterotopic bone, Didronel retards the progression of immature lesions and reduces the severity by at least half. Follow-up data (at least 9 months posttherapy) suggest these benefits persist. In total hip replacement patients, Didronel does not promote loosening of the prosthesis or impede trochanteric reattachment. In spinal cord injury patients, Didronel does not inhibit fracture healing or stabilization of the spine.

Launch Date

2.4192E11
Preventing
DIDRONEL

Approved Use

Didronel is indicated for the treatment of symptomatic Paget’s disease of bone and in the prevention and treatment of heterotopic ossification following total hip replacement or due to spinal cord injury. Didronel is not approved for the treatment of osteoporosis. Paget’s Disease: Didronel is indicated for the treatment of symptomatic Paget's disease of bone. Didronel therapy usually arrests or significantly impedes the disease process as evidenced by: --Symptomatic relief, including decreased pain and/or increased mobility (experienced by 3 out of 5 patients). --Reductions in serum alkaline phosphatase and urinary hydroxyproline levels (30 percent or more in 4 out of 5 patients). --Histomorphometry showing reduced numbers of osteoclasts and osteoblasts, and more lamellar bone formation. Bone scans showing reduced radionuclide uptake at pagetic lesions. In addition, reductions in pagetically elevated cardiac output and skin temperature have been observed in some patients. In many patients, the disease process will be suppressed for a period of at least 1 year following cessation of therapy. The upper limit of this period has not been determined. The effects of the Didronel treatment in patients with asymptomatic Paget's disease have not been studied. However, Didronel treatment of such patients may be warranted if extensive involvement threatens irreversible neurologic damage, major joints, or major weight-bearing bones. Heterotopic Ossification: Didronel is indicated in the prevention and treatment of heterotopic ossification following total hip replacement or due to spinal cord injury. Didronel reduces the incidence of clinically important heterotopic bone by about two-thirds. Among those patients who form heterotopic bone, Didronel retards the progression of immature lesions and reduces the severity by at least half. Follow-up data (at least 9 months posttherapy) suggest these benefits persist. In total hip replacement patients, Didronel does not promote loosening of the prosthesis or impede trochanteric reattachment. In spinal cord injury patients, Didronel does not inhibit fracture healing or stabilization of the spine.

Launch Date

2.4192E11
PubMed

PubMed

TitleDatePubMed
Possibility of "distraction arthrogenesis": first report in rabbit model.
2001
Effect of menatetrenone on bone mineral density and incidence of vertebral fractures in postmenopausal women with osteoporosis: a comparison with the effect of etidronate.
2001
Etidronate for treating and preventing postmenopausal osteoporosis.
2001
Effect of intermittent cyclical treatment with etidronate disodium (HEBP) and calcium plus alphacalcidol in postmenopausal osteoporosis.
2001
Cost effectiveness of nasal calcitonin in postmenopausal women: use of Cochrane Collaboration methods for meta-analysis within economic evaluation.
2001
Guidelines for treatment of osteoporosis in men.
2001 Aug
186Re-1,4,8,11-tetraaza cyclotetradecyl-1,4,8,11-tetramethylene phosphonic acid: a novel agent for possible use in metastatic bone-pain palliation.
2001 Aug
Osteoporosis in children and adolescent girls: case report of idiopathic juvenile osteoporosis and review of the literature.
2001 Aug
Subcutaneous fat necrosis of the newborn following hypothermia and complicated by pain and hypercalcaemia.
2001 Aug
Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis.
2001 Dec
[Therapy of osteoporosis. Risk factors alone are not an indication].
2001 Dec 6
[Fluorides and bisphosphonates in the treatment of osteoporosis].
2001 Jul
[Tumor-induced hypercalcemia. Review of bisphosphonate treatment].
2001 Jul
A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer.
2001 Jul
Role of bisphosphonates and calcitonin in the prevention and treatment of osteoporosis.
2001 Jul
[Bisphosphonate treatment prevents hip fractures in 70-79 year old women with osteoporotic vertebral fractures].
2001 Jul 14
Clinical effect of etidronate on alveolar pyorrhoea associated with chronic marginal periodontitis: report of four cases.
2001 Jul-Aug
[Alternatives to hormonal treatment for the prevention of postmenopausal osteoporosis: the bisphosphonates].
2001 Nov
Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage.
2001 Nov
Familial fibrodysplasia ossificans progressiva: trial with etidronate disodium.
2001 Nov
Role of alendronate and risedronate in preventing and treating osteoporosis.
2001 Nov
Extracellular signal-regulated kinases and calcium channels are involved in the proliferative effect of bisphosphonates on osteoblastic cells in vitro.
2001 Nov
Rhenium-188 HEDP to treat painful bone metastases.
2001 Nov
Conventional treatment of hypercalcemia of malignancy.
2001 Nov 15
Advances in the biology and treatment of myeloma bone disease.
2001 Nov 15
A method to assess the proportion of treatment effect explained by a surrogate endpoint.
2001 Nov 15
[Economic aspects of osteoporosis therapy. What does a prevented fracture cost?].
2001 Nov 22
Risedronate treatment and extended fracture protection in postmenopausal women.
2001 Nov-Dec
Treatment of osteoporosis in men with fluoride alone or in combination with bisphosphonates.
2001 Oct
Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy.
2001 Oct
Alendronate for the treatment of osteoporosis in men.
2001 Oct
Comparative efficacy and safety study of etidronate and alendronate in postmenopausal osteoporosis. effect of adding hormone replacement therapy.
2001 Oct
Low-dose oral etidronate therapy for immobilization hypercalcaemia associated with Guillain-Barré syndrome.
2001 Oct
Maintenance of cancellous bone in ovariectomized, human parathyroid hormone [hPTH(1-84)]-treated rats by estrogen, risedronate, or reduced hPTH.
2001 Oct
Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: a model of bisphosphonate-induced gastrointestinal toxicity.
2001 Oct
Painful multifocal arthritis: therapy with rhenium 186 hydroxyethylidenediphosphonate ((186)Re HEDP) after failed treatment with medication--initial results of a prospective study.
2001 Oct
[Osteoporosis. Fracture as alarm signal].
2001 Oct 11
Risedronate: a new oral bisphosphonate.
2001 Sep
Bisphosphonates for osteoporosis.
2001 Sep
The diagnosis of Paget's disease.
2001 Sep
Effects of high-dose etidronate treatment on microdamage accumulation and biomechanical properties in beagle bone before occurrence of spontaneous fractures.
2001 Sep
Alendronate does not interfere with 99mTc-methylene diphosphonate bone scanning.
2001 Sep
Pharmacologic therapy for the treatment and prevention of osteoporosis.
2001 Sep
Vgamma2Vdelta2 T-cell receptor-mediated recognition of aminobisphosphonates.
2001 Sep 1
Zinc diphosphonates templated by organic amines: syntheses and characterizations of [NH3(CH2)2NH3]Zn(hedpH2)2*2H2O and [NH3(CH2)nNH3(CH2)nNH3]Zn2(hedpH)2*2H2O (n=4,5,6) (hedp=1-hydroxyethylidenediphophonate).
2001 Sep 10
[Risedronate now also approved for hip fractures. Study discloses significant risk reduction in proximal femoral neck fractures].
2001 Sep 6
[Optimizing treatment of osteoporosis. Rapidly effective therapy lowers fracture risk in 1 year up to 70%].
2001 Sep 6
Refractory heterotopic ossification with complications.
2001 Summer
Positive effect of etidronate therapy is maintained after drug is terminated in patients using corticosteroids.
2001 Winter
Discovery of a high molecular weight complex of calcium, phosphate, fetuin, and matrix gamma-carboxyglutamic acid protein in the serum of etidronate-treated rats.
2002 Feb 8
Patents

Patents

Sample Use Guides

should be taken as a single, oral dose. Paget’s Disease: Initial Treatment Regimens: 5 to 10 mg/kg/day, not to exceed 6 months, or 11 to 20 mg/kg/day, not to exceed 3 months. The recommended initial dose is 5 mg/kg/day for a period not to exceed 6 months. Doses above 10 mg/kg/day should be reserved for when 1) lower doses are ineffective or 2) there is an overriding need to suppress rapid bone turnover (especially when irreversible neurologic damage is possible) or reduce elevated cardiac output. Doses in excess of 20 mg/kg/day are not recommended.
Route of Administration: Oral
In vitro cytotoxicity of etidronic acid to MCF-7 cells was estimated on the basis of clonogenicity assays, while cell cycle effects were determined by using flow cytometry. A 24-hour treatment with etidronic acid (10 mM) with or without strontium chloride was cytototoxic to MCF-7cells. Etidronic acid (1, 10 mM) caused a decrease in the S-phase population and an increase in the G2/M population. Treatment of MCF-7 human breast cancer cells with etidronic acid (10 mM) for six hours caused mutations in exons 6 and 8 of the p53 gene in MCF-7 cells.
Name Type Language
ETIDRONIC ACID
HSDB   INCI   INN   MART.   MI   USAN   WHO-DD  
INCI   INN   USAN  
Official Name English
ETIDRONATE
VANDF  
Common Name English
ETIDRONIC ACID [INCI]
Common Name English
M05BA01
Code English
(1-HYDROXYETHYLIDENE)DIPHOSPHONIC ACID
Systematic Name English
HYDROXYETHYLIDENE-1,1-DIPHOSPHONIC ACID
Systematic Name English
ETIDRONIC ACID [INN]
Common Name English
ETIDRONIC ACID [HSDB]
Common Name English
(1-HYDROXY-ETHYLIDENE)DIPHOSPHONIC ACID
Systematic Name English
NSC-227995
Code English
PHOSPHONIC ACID, (1-HYDROXYETHYLIDENE)BIS-
Common Name English
ETIDRONIC ACID [USAN]
Common Name English
PHOSPHONIC ACID, P,P'-(1-HYDROXYETHYLIDENE)BIS-
Systematic Name English
ETIDRONATE [VANDF]
Common Name English
1-HYDROXYETHANE-1,1-BISPHOSPHONIC ACID
Systematic Name English
ETIDRONIC ACID [WHO-DD]
Common Name English
ETIDRONIC ACID [MART.]
Common Name English
OEDP
Common Name English
ETIDRONIC ACID [MI]
Common Name English
Classification Tree Code System Code
Food Contact Sustance Notif, (FCN No.) FCN NO. 1096
Created by admin on Sat Jun 26 14:28:01 UTC 2021 , Edited by admin on Sat Jun 26 14:28:01 UTC 2021
Food Contact Sustance Notif, (FCN No.) FCN NO. 699
Created by admin on Sat Jun 26 14:28:01 UTC 2021 , Edited by admin on Sat Jun 26 14:28:01 UTC 2021
Food Contact Sustance Notif, (FCN No.) FCN NO. 1144
Created by admin on Sat Jun 26 14:28:01 UTC 2021 , Edited by admin on Sat Jun 26 14:28:01 UTC 2021
Food Contact Sustance Notif, (FCN No.) FCN NO. 691
Created by admin on Sat Jun 26 14:28:01 UTC 2021 , Edited by admin on Sat Jun 26 14:28:01 UTC 2021
Food Contact Sustance Notif, (FCN No.) FCN NO. 1247
Created by admin on Sat Jun 26 14:28:01 UTC 2021 , Edited by admin on Sat Jun 26 14:28:01 UTC 2021
WHO-ATC M05BB01
Created by admin on Sat Jun 26 14:28:01 UTC 2021 , Edited by admin on Sat Jun 26 14:28:01 UTC 2021
WHO-VATC QM05BA01
Created by admin on Sat Jun 26 14:28:01 UTC 2021 , Edited by admin on Sat Jun 26 14:28:01 UTC 2021
LIVERTOX 386
Created by admin on Sat Jun 26 14:28:01 UTC 2021 , Edited by admin on Sat Jun 26 14:28:01 UTC 2021
NDF-RT N0000175579
Created by admin on Sat Jun 26 14:28:01 UTC 2021 , Edited by admin on Sat Jun 26 14:28:01 UTC 2021
Food Contact Sustance Notif, (FCN No.) FCN NO. 561
Created by admin on Sat Jun 26 14:28:01 UTC 2021 , Edited by admin on Sat Jun 26 14:28:01 UTC 2021
Food Contact Sustance Notif, (FCN No.) FCN NO. 1081
Created by admin on Sat Jun 26 14:28:01 UTC 2021 , Edited by admin on Sat Jun 26 14:28:01 UTC 2021
Food Contact Sustance Notif, (FCN No.) FCN NO. 1082
Created by admin on Sat Jun 26 14:28:01 UTC 2021 , Edited by admin on Sat Jun 26 14:28:01 UTC 2021
NCI_THESAURUS C443
Created by admin on Sat Jun 26 14:28:01 UTC 2021 , Edited by admin on Sat Jun 26 14:28:01 UTC 2021
Food Contact Sustance Notif, (FCN No.) FCN NO. 1094
Created by admin on Sat Jun 26 14:28:01 UTC 2021 , Edited by admin on Sat Jun 26 14:28:01 UTC 2021
Food Contact Sustance Notif, (FCN No.) FCN NO. 625
Created by admin on Sat Jun 26 14:28:01 UTC 2021 , Edited by admin on Sat Jun 26 14:28:01 UTC 2021
Food Contact Sustance Notif, (FCN No.) FCN NO. 951
Created by admin on Sat Jun 26 14:28:01 UTC 2021 , Edited by admin on Sat Jun 26 14:28:01 UTC 2021
Food Contact Sustance Notif, (FCN No.) FCN NO. 724
Created by admin on Sat Jun 26 14:28:01 UTC 2021 , Edited by admin on Sat Jun 26 14:28:01 UTC 2021
Food Contact Sustance Notif, (FCN No.) FCN NO. 670
Created by admin on Sat Jun 26 14:28:01 UTC 2021 , Edited by admin on Sat Jun 26 14:28:01 UTC 2021
Food Contact Sustance Notif, (FCN No.) FCN NO. 908
Created by admin on Sat Jun 26 14:28:01 UTC 2021 , Edited by admin on Sat Jun 26 14:28:01 UTC 2021
Food Contact Sustance Notif, (FCN No.) FCN NO. 1089
Created by admin on Sat Jun 26 14:28:01 UTC 2021 , Edited by admin on Sat Jun 26 14:28:01 UTC 2021
Food Contact Sustance Notif, (FCN No.) FCN NO. 641
Created by admin on Sat Jun 26 14:28:01 UTC 2021 , Edited by admin on Sat Jun 26 14:28:01 UTC 2021
Food Contact Sustance Notif, (FCN No.) FCN NO. 993
Created by admin on Sat Jun 26 14:28:01 UTC 2021 , Edited by admin on Sat Jun 26 14:28:01 UTC 2021
Food Contact Sustance Notif, (FCN No.) FCN NO. 1236
Created by admin on Sat Jun 26 14:28:01 UTC 2021 , Edited by admin on Sat Jun 26 14:28:01 UTC 2021
WHO-ATC M05BA01
Created by admin on Sat Jun 26 14:28:01 UTC 2021 , Edited by admin on Sat Jun 26 14:28:01 UTC 2021
Food Contact Sustance Notif, (FCN No.) FCN NO. 921
Created by admin on Sat Jun 26 14:28:01 UTC 2021 , Edited by admin on Sat Jun 26 14:28:01 UTC 2021
Food Contact Sustance Notif, (FCN No.) FCN NO. 1035
Created by admin on Sat Jun 26 14:28:01 UTC 2021 , Edited by admin on Sat Jun 26 14:28:01 UTC 2021
Food Contact Sustance Notif, (FCN No.) FCN NO. 1132
Created by admin on Sat Jun 26 14:28:01 UTC 2021 , Edited by admin on Sat Jun 26 14:28:01 UTC 2021
Food Contact Sustance Notif, (FCN No.) FCN NO. 801
Created by admin on Sat Jun 26 14:28:01 UTC 2021 , Edited by admin on Sat Jun 26 14:28:01 UTC 2021
Food Contact Sustance Notif, (FCN No.) FCN NO. 323
Created by admin on Sat Jun 26 14:28:01 UTC 2021 , Edited by admin on Sat Jun 26 14:28:01 UTC 2021
Food Contact Sustance Notif, (FCN No.) FCN NO. 1093
Created by admin on Sat Jun 26 14:28:01 UTC 2021 , Edited by admin on Sat Jun 26 14:28:01 UTC 2021
Food Contact Sustance Notif, (FCN No.) FCN NO. 728
Created by admin on Sat Jun 26 14:28:01 UTC 2021 , Edited by admin on Sat Jun 26 14:28:01 UTC 2021
Food Contact Sustance Notif, (FCN No.) FCN NO. 447
Created by admin on Sat Jun 26 14:28:01 UTC 2021 , Edited by admin on Sat Jun 26 14:28:01 UTC 2021
WHO-VATC QM05BB01
Created by admin on Sat Jun 26 14:28:01 UTC 2021 , Edited by admin on Sat Jun 26 14:28:01 UTC 2021
Food Contact Sustance Notif, (FCN No.) FCN NO. 880
Created by admin on Sat Jun 26 14:28:01 UTC 2021 , Edited by admin on Sat Jun 26 14:28:01 UTC 2021
Food Contact Sustance Notif, (FCN No.) FCN NO. 887
Created by admin on Sat Jun 26 14:28:01 UTC 2021 , Edited by admin on Sat Jun 26 14:28:01 UTC 2021
NCI_THESAURUS C67439
Created by admin on Sat Jun 26 14:28:01 UTC 2021 , Edited by admin on Sat Jun 26 14:28:01 UTC 2021
Food Contact Sustance Notif, (FCN No.) FCN NO. 140
Created by admin on Sat Jun 26 14:28:01 UTC 2021 , Edited by admin on Sat Jun 26 14:28:01 UTC 2021
NDF-RT N0000007707
Created by admin on Sat Jun 26 14:28:01 UTC 2021 , Edited by admin on Sat Jun 26 14:28:01 UTC 2021
Food Contact Sustance Notif, (FCN No.) FCN NO. 911
Created by admin on Sat Jun 26 14:28:01 UTC 2021 , Edited by admin on Sat Jun 26 14:28:01 UTC 2021
Code System Code Type Description
ECHA (EC/EINECS)
220-552-8
Created by admin on Sat Jun 26 14:28:01 UTC 2021 , Edited by admin on Sat Jun 26 14:28:01 UTC 2021
PRIMARY
PUBCHEM
3305
Created by admin on Sat Jun 26 14:28:01 UTC 2021 , Edited by admin on Sat Jun 26 14:28:01 UTC 2021
PRIMARY
INN
2758
Created by admin on Sat Jun 26 14:28:01 UTC 2021 , Edited by admin on Sat Jun 26 14:28:01 UTC 2021
PRIMARY
FDA UNII
M2F465ROXU
Created by admin on Sat Jun 26 14:28:01 UTC 2021 , Edited by admin on Sat Jun 26 14:28:01 UTC 2021
PRIMARY
MERCK INDEX
M5182
Created by admin on Sat Jun 26 14:28:01 UTC 2021 , Edited by admin on Sat Jun 26 14:28:01 UTC 2021
PRIMARY Merck Index
DRUG BANK
DB01077
Created by admin on Sat Jun 26 14:28:01 UTC 2021 , Edited by admin on Sat Jun 26 14:28:01 UTC 2021
PRIMARY
MESH
D012968
Created by admin on Sat Jun 26 14:28:01 UTC 2021 , Edited by admin on Sat Jun 26 14:28:01 UTC 2021
PRIMARY
LACTMED
Etidronate
Created by admin on Sat Jun 26 14:28:01 UTC 2021 , Edited by admin on Sat Jun 26 14:28:01 UTC 2021
PRIMARY
EPA CompTox
2809-21-4
Created by admin on Sat Jun 26 14:28:01 UTC 2021 , Edited by admin on Sat Jun 26 14:28:01 UTC 2021
PRIMARY
DRUG CENTRAL
1098
Created by admin on Sat Jun 26 14:28:01 UTC 2021 , Edited by admin on Sat Jun 26 14:28:01 UTC 2021
PRIMARY
HSDB
5898
Created by admin on Sat Jun 26 14:28:01 UTC 2021 , Edited by admin on Sat Jun 26 14:28:01 UTC 2021
PRIMARY
IUPHAR
7184
Created by admin on Sat Jun 26 14:28:01 UTC 2021 , Edited by admin on Sat Jun 26 14:28:01 UTC 2021
PRIMARY
NCI_THESAURUS
C1332
Created by admin on Sat Jun 26 14:28:01 UTC 2021 , Edited by admin on Sat Jun 26 14:28:01 UTC 2021
PRIMARY
RXCUI
1356715
Created by admin on Sat Jun 26 14:28:01 UTC 2021 , Edited by admin on Sat Jun 26 14:28:01 UTC 2021
PRIMARY
ChEMBL
CHEMBL871
Created by admin on Sat Jun 26 14:28:01 UTC 2021 , Edited by admin on Sat Jun 26 14:28:01 UTC 2021
PRIMARY
CAS
2809-21-4
Created by admin on Sat Jun 26 14:28:01 UTC 2021 , Edited by admin on Sat Jun 26 14:28:01 UTC 2021
PRIMARY
RXCUI
42682
Created by admin on Sat Jun 26 14:28:01 UTC 2021 , Edited by admin on Sat Jun 26 14:28:01 UTC 2021
ALTERNATIVE
EVMPD
SUB07299MIG
Created by admin on Sat Jun 26 14:28:01 UTC 2021 , Edited by admin on Sat Jun 26 14:28:01 UTC 2021
PRIMARY